UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053225
Receipt number R000056010
Scientific Title The effect of intensive inpatient rehabilitation after botulinum toxin type A administration for patients with chronic motor paralysis after stroke
Date of disclosure of the study information 2024/01/01
Last modified on 2023/12/26 13:17:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of intensive inpatient rehabilitation after botulinum toxin type A administration for patients with chronic motor paralysis after stroke

Acronym

The effect of intensive inpatient rehabilitation after botulinum toxin type A administration

Scientific Title

The effect of intensive inpatient rehabilitation after botulinum toxin type A administration for patients with chronic motor paralysis after stroke

Scientific Title:Acronym

The effect of intensive inpatient rehabilitation after botulinum toxin type A administration

Region

Japan


Condition

Condition

patient with chronic motor paralysis after stroke

Classification by specialty

Rehabilitation medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effect of the amount and content of intensive inpatient rehabilitation after botulinum toxin type A administration for chronic motor paralysis after stroke.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Modified Ashworth Scale measured 4 and 8 weeks after administration of botulinum toxin type A

Key secondary outcomes

Global Rating of Change scale, Fugl-Meyer Assessment, Action Research Arm Test, Box and Block Test, Motor Activity Log, 10m walk test, Euro Qol-5D


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Device,equipment Maneuver

Interventions/Control_1

1) Botulinum toxin A (BoNT-A) therapy
Total dosage 400 units or less

2) Intensive rehabilitation
Intensive rehabilitation will be performed daily, 120 minutes/day for 28 days. The program's contents are KINVIS therapy (20 minutes) and individual rehabilitation (100 minutes).

Interventions/Control_2

1) Botulinum toxin A (BoNT-A) therapy
Total dosage 400 units or less

2) Intensive rehabilitation
Intensive rehabilitation will be performed daily, 120 minutes/day for 28 days. The program's content is individual rehabilitation (120 minutes).

Interventions/Control_3

1) Botulinum toxin A (BoNT-A) therapy
Total dosage 400 units or less

2) Intensive rehabilitation
Intensive rehabilitation will be performed daily, 120 minutes/day for 56 days. The program's contents are KINVIS therapy (20 minutes) and individual rehabilitation (100 minutes).

Interventions/Control_4

1) Botulinum toxin A (BoNT-A) therapy
Total dosage 400 units or less

2) Intensive rehabilitation
Intensive rehabilitation will be performed daily, 120 minutes/day for 56 days. The program's content is individual rehabilitation (120 minutes).

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients in the chronic phase of stroke who are visiting our outpatient clinic and whose Modified Ashworth Scale (MAS) score of the target spastic muscle is between 1+ (mild hypertonia with resistance less than 1/2 the range of motion) and less than 4 (affected area is rigid and difficult to flex and extend), without significant cognitive dysfunction (Mini-Mental State Examination; MSE 24 points or higher).

Key exclusion criteria

Patients treated for spasticity with oral muscle relaxants, motor point block with phenol, intrathecal baclofen pump therapy within the last three months

Target sample size

57


Research contact person

Name of lead principal investigator

1st name Sho
Middle name
Last name Maruyama

Organization

Shonan-Keiiku Hospital

Division name

Department of Rehabilitation

Zip code

252-0816

Address

4360 Endo, Fujisawa city, Kanagawa pref., Japan

TEL

0466480050

Email

s-maruyama@keiiku.gr.jp


Public contact

Name of contact person

1st name Sho
Middle name
Last name Maruyama

Organization

Shonan-Keiiku Hospital

Division name

Department of Rehabilitation

Zip code

252-0816

Address

4360 Endo, Fujisawa city, Kanagawa pref., Japan

TEL

0466480050

Homepage URL


Email

s-maruyama@keiiku.gr.jp


Sponsor or person

Institute

Department of Rehabilitation, Shonan-Keiiku Hospital

Institute

Department

Personal name



Funding Source

Organization

Department of Rehabilitation, Shonan-Keiiku Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kitasato University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shonan-Keiiku Hospital

Address

4360 Endo, Fujisawa city, Kanagawa pref., Japan

Tel

0466480050

Email

s-maruyama@keiiku.gr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 09 Month 20 Day

Date of IRB

2022 Year 09 Month 20 Day

Anticipated trial start date

2024 Year 01 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 26 Day

Last modified on

2023 Year 12 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056010


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name